|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MYO18A |
Gene summary for MYO18A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MYO18A | Gene ID | 399687 |
| Gene name | myosin XVIIIA | |
| Gene Alias | MAJN | |
| Cytomap | 17q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q92614 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 399687 | MYO18A | NAFLD1 | Human | Liver | NAFLD | 1.27e-09 | 6.05e-01 | -0.04 |
| 399687 | MYO18A | S41 | Human | Liver | Cirrhotic | 2.78e-03 | 3.37e-01 | -0.0343 |
| 399687 | MYO18A | HCC1_Meng | Human | Liver | HCC | 3.09e-10 | -4.09e-02 | 0.0246 |
| 399687 | MYO18A | HCC2 | Human | Liver | HCC | 1.88e-08 | 2.94e+00 | 0.5341 |
| 399687 | MYO18A | S014 | Human | Liver | HCC | 3.06e-04 | 2.87e-01 | 0.2254 |
| 399687 | MYO18A | S015 | Human | Liver | HCC | 6.99e-03 | 2.20e-01 | 0.2375 |
| 399687 | MYO18A | S016 | Human | Liver | HCC | 2.32e-04 | 2.28e-01 | 0.2243 |
| 399687 | MYO18A | S027 | Human | Liver | HCC | 2.51e-02 | 4.81e-01 | 0.2446 |
| 399687 | MYO18A | S028 | Human | Liver | HCC | 2.75e-19 | 6.41e-01 | 0.2503 |
| 399687 | MYO18A | S029 | Human | Liver | HCC | 4.66e-16 | 8.34e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00481936 | Liver | NAFLD | Golgi vesicle transport | 66/1882 | 296/18723 | 3.66e-10 | 9.30e-08 | 66 |
| GO:00071636 | Liver | NAFLD | establishment or maintenance of cell polarity | 46/1882 | 218/18723 | 8.80e-07 | 4.60e-05 | 46 |
| GO:00300106 | Liver | NAFLD | establishment of cell polarity | 34/1882 | 143/18723 | 1.41e-06 | 6.56e-05 | 34 |
| GO:0007030 | Liver | NAFLD | Golgi organization | 36/1882 | 157/18723 | 1.76e-06 | 7.68e-05 | 36 |
| GO:00310326 | Liver | NAFLD | actomyosin structure organization | 41/1882 | 196/18723 | 4.26e-06 | 1.66e-04 | 41 |
| GO:00512227 | Liver | NAFLD | positive regulation of protein transport | 55/1882 | 303/18723 | 1.07e-05 | 3.35e-04 | 55 |
| GO:19049517 | Liver | NAFLD | positive regulation of establishment of protein localization | 55/1882 | 319/18723 | 4.79e-05 | 1.14e-03 | 55 |
| GO:00069007 | Liver | NAFLD | vesicle budding from membrane | 17/1882 | 61/18723 | 7.31e-05 | 1.52e-03 | 17 |
| GO:00160505 | Liver | NAFLD | vesicle organization | 50/1882 | 300/18723 | 2.42e-04 | 4.06e-03 | 50 |
| GO:0090161 | Liver | NAFLD | Golgi ribbon formation | 6/1882 | 13/18723 | 9.41e-04 | 1.12e-02 | 6 |
| GO:0050764 | Liver | NAFLD | regulation of phagocytosis | 19/1882 | 95/18723 | 2.61e-03 | 2.41e-02 | 19 |
| GO:00355926 | Liver | NAFLD | establishment of protein localization to extracellular region | 52/1882 | 360/18723 | 4.80e-03 | 3.81e-02 | 52 |
| GO:00507147 | Liver | NAFLD | positive regulation of protein secretion | 24/1882 | 137/18723 | 4.89e-03 | 3.85e-02 | 24 |
| GO:0050766 | Liver | NAFLD | positive regulation of phagocytosis | 14/1882 | 66/18723 | 5.28e-03 | 4.08e-02 | 14 |
| GO:00093066 | Liver | NAFLD | protein secretion | 51/1882 | 359/18723 | 7.17e-03 | 4.96e-02 | 51 |
| GO:004819311 | Liver | Cirrhotic | Golgi vesicle transport | 153/4634 | 296/18723 | 1.02e-23 | 6.43e-21 | 153 |
| GO:001605011 | Liver | Cirrhotic | vesicle organization | 133/4634 | 300/18723 | 7.35e-14 | 6.41e-12 | 133 |
| GO:000690012 | Liver | Cirrhotic | vesicle budding from membrane | 41/4634 | 61/18723 | 3.12e-12 | 2.25e-10 | 41 |
| GO:190495112 | Liver | Cirrhotic | positive regulation of establishment of protein localization | 135/4634 | 319/18723 | 3.20e-12 | 2.28e-10 | 135 |
| GO:005122212 | Liver | Cirrhotic | positive regulation of protein transport | 126/4634 | 303/18723 | 6.85e-11 | 3.77e-09 | 126 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MYO18A | SNV | Missense_Mutation | novel | c.2520N>G | p.Ile840Met | p.I840M | Q92614 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| MYO18A | SNV | Missense_Mutation | c.1282N>T | p.Arg428Cys | p.R428C | Q92614 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD | |
| MYO18A | SNV | Missense_Mutation | c.4507N>C | p.Glu1503Gln | p.E1503Q | Q92614 | protein_coding | tolerated(0.48) | benign(0.099) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| MYO18A | SNV | Missense_Mutation | c.625N>T | p.Pro209Ser | p.P209S | Q92614 | protein_coding | tolerated_low_confidence(0.43) | benign(0) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| MYO18A | SNV | Missense_Mutation | c.5254N>G | p.Gln1752Glu | p.Q1752E | Q92614 | protein_coding | tolerated(0.19) | benign(0.247) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| MYO18A | SNV | Missense_Mutation | c.2815N>C | p.Glu939Gln | p.E939Q | Q92614 | protein_coding | tolerated(0.09) | benign(0.07) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MYO18A | SNV | Missense_Mutation | novel | c.3789C>G | p.Ile1263Met | p.I1263M | Q92614 | protein_coding | deleterious(0.04) | benign(0.216) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MYO18A | SNV | Missense_Mutation | novel | c.5101G>C | p.Ala1701Pro | p.A1701P | Q92614 | protein_coding | tolerated(0.14) | probably_damaging(1) | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MYO18A | SNV | Missense_Mutation | c.6161N>T | p.Ala2054Val | p.A2054V | Q92614 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-AR-A1AQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MYO18A | SNV | Missense_Mutation | novel | c.1865A>G | p.Asn622Ser | p.N622S | Q92614 | protein_coding | tolerated(0.46) | benign(0.056) | TCGA-B6-A0X0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |